BerGenBio  to present new NSCLC and AMLclinical data and biomarker data from phase II development programme with selective AXL inhibitor Bemcentinib at ASCO2019

Bergen, May 23, 2019

BerGenBio notes the publication of abstracts relating to new interim clinical and biomarker data that the company and its collaborators will present from its extensive Phase II clinical development programme with bemcentinib at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago, Illinois (31 May – 4 June 2019).